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 Periodontitis is an inflammatory condition which results in the destruction of 
the tooth supporting structures. The mechanisms underlying this destructive process 
involves both direct tissue damage resulting from plaque bacterial products, and 
indirect damage through bacterial induction of the host inflammatory and immune 
responses. This host response involves complex interactions between cells, the 
extracellular matrix and circulating cytokines.[1]  
 The elimination of periodontopathogens containing biofilm remains the first 
goal of periodontal therapy. Although mechanical debridement such as Scaling and 
Root Planing (SRP) reduces the level of subgingival bacteria and thereby 
inflammatory mediators, it does not completely eliminate the pathogens that resides 
deep into the connective tissue.[2]  
 The limitations of conventional periodontal therapy led to the emergence of 
many chemical agents such as antiseptics, NSAIDS and antibiotics. Drugs were used 
both systemically and locally. Systemic delivery requires the administration of larger 
doses to obtain required concentration of drug at the site of disease. This has led to 
the development of bacterial resistance, drug interactions and inconsistent patient 
compliance.[3] In order to overcome the drawbacks of systemic administration, local 
delivery system was introduced.  
 In the Local Drug Delivery systems, the drug can be delivered to the site of 
disease activity at a required concentration and can facilitate prolonged drug 
delivery. Although different chemical agents are available in different forms such as 
gels, strips, microcapsules, fibres and films, search for alternative products continues 
and natural phytochemicals isolated from plants are considered as good alternatives 
to synthetic chemicals.[4]  
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 Among the many herbs available, Pomegranate extracts have been reported 
to have many beneficial health effects, exhibiting antioxidant, anti-inflammation, 
antiproliferative, and DNA repair activities, which are generally attributed to the 
high polyphenol content.[5]   
 Cytokines are soluble proteins produced by the structural and inflammatory 
cells, into extracellular fluid, where they exert their effects on the same cells or on 
neighbouring cells by interacting with specific receptors. The role of cytokines in 
maintenance of tissue homeostasis requires delicate balance between catabolic and 
anabolic activities.    
 The inflammatory mediators and cytokines manifest potent pro-inflammatory 
and catabolic activity and may play a key role in local amplification of the immune 
response as well as periodontal tissue breakdown. Among the chemical mediators 
released by the host cells in response to inflammatory stimulus, IL-1 beta is thought 
to play a major role in the pathogenesis of periodontal diseases. IL-1 beta have been 
demonstrated at increased levels in inflamed gingival tissues and gingival crevicular 
fluid. It is one of the most potent inducers of bone resorption and promotes 
connective tissue degradation through the induction of Matrix metalloproteinase 
(MMPs) gene expression.[6] 
 Pomegranate extract exhibited anti inflammatory activity through inhibition 
of NF-kB activity and prevention of ERK-1 and ERK-2 activation. Pomegranate 
extract have been shown to inhibit the IL-1β induced destruction of proteoglycan, 
expression of MMPs at the cellular level, NO and PGE2 production.[7] Pomegranate 
therefore could be beneficial in treating periodontitis as it possess excellent anti-
inflammatory effect.  
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 Reactive oxygen species (ROS) plays an important role in tissue destruction 
when produced in excess. Antioxidants are groups of substances that are able to 
prevent the oxidation reaction of ROS, thereby offering protection. Currently, there 
is a growing interest in the linkage between antioxidants and periodontal disease. A 
significant antioxidant enzyme within mammalian tissues is Superoxide Dismutase, 
which catalyzes the dismutation of O2− to H2O2 and O2. Superoxide Dismutase 
(SOD) has also been localized within the human periodontal ligament and may 
represent an important defense mechanism within gingival cells against superoxide 
release.[8]  
 The Superoxide Dismutase activity significantly improved following 
periodontal therapy, suggesting a positive response to nonsurgical periodontal 
therapy. Therefore, treatment of periodontal disease reduces oxidative stress by a 
concomitant reduction in inflammatory load by enhancing antioxidant levels. 
Pomegranate was found to exert potent antioxidant activity against lipid 
peroxidation.[9] The free radical scavenging activity of pomegranate depends on the 
polyphenols that involves electron donation to free radicals that converts them to 
relatively more stable compounds. Pomegranate extract exhibits inhibition of LPS 
induced oxidative stress by reducing ROS and NO generation and increasing 
Superoxide Dismutase 1 mRNA expression.   
 Pomegranate is rich in polyphenols such as Ellagitanins, Punicalagins, 
Punicallin and Gallotanin. The high antioxidant and anti inflammatory activity of 
pomegranate is due to high content of punicalagin.[10] Although various forms of 
pomegranate extract has been used, in our present study it is used as a gel form since 
they can deliver the drug to the site of disease activity at a required concentration 
and also can facilitate prolonged drug delivery.   
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 Based on the anti-inflammatory and antioxidant properties of punicalagin, 
the present study is designed to analyse the levels of IL-1 beta and Superoxide 
Dismutase in GCF after 21 days of subgingival application with punicalagin gel, as 
an adjunct to Scaling and Root Planing in patients with Chronic Periodontitis.  
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The aim of the present study is 
1. To evaluate the effects of subgingival application of punicalagin 
gelatin film as an adjunct to Scaling and Root Planing (SRP) 
compared with SRP alone in patients with Chronic Periodontitis. 
2. To compare the changes in Probing Pocket Depth and Clinical 
Attachment Level gain following therapy. 
3. To assess the anti-inflammatory and anti-oxidant effect of 
punicalagin gelatin film on IL-1β and SOD levels by ELISA method. 
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Chronic Periodontitis is an infectious disease, resulting in inflammation within the 
supporting tissues of the teeth, ultimately resulting in progressive attachment loss 
and bone loss and is characterized by periodontal pocket formation and/or recession 
of the gingiva. The goal of periodontal therapy is to get rid of the microbial etiology 
and control or eliminate disease progression. Apart from this, periodontal treatment 
should restore the lost form, function, esthetics and comfort. Scaling and Root 
Planning is the most widely used approach that effectively decreases the microbial 
load.  
SCALING AND ROOT PLANING 
 Scaling and Root Planing, otherwise known as conventional, Non-Surgical 
Periodontal Therapy, is the process of removing or eliminating the etiologic agents –
 dental plaque, its products, and calculus – which cause inflammation, thus helping 
to establish a periodontium that is in remission of periodontal disease. 
 Tagge DL et al., (1975)[11] evaluated the response of soft tissue pockets to 
treatment by oral hygiene procedures alone or by oral hygiene procedures and root 
planning. The combination of oral hygiene and root planning resulted in a more 
significant clinical outcome when compared to oral hygiene procedure alone. 
 Lindhe J et al., (1982)[12] in a 24 month study compared the effects of 
Scaling and Root Planing to the Widman flap procedure. During the active treatment 
and subsequent 6 months, participants received a professional tooth cleaning every 2 
weeks and prophylaxis every 3 months thereafter for the remainder of the study. It 
was found that Scaling and Root Planing procedures were almost as effective as the 
Widman flap procedure in preventing further attachment loss. The results also 
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showed that both Probing Depth reductions and gain in Clinical Attachment Levels 
were more pronounced in initially deep pockets than in an initially shallow pockets.    
 Christgau M et al., (2006)[13] evaluated the clinical and microbiological 
healing outcomes following Non Surgical Periodontal Therapy using a modified 
sonic scaler system versus Scaling and Root Planning with hand instruments. The 
study compared twenty Chronic Periodontitis patients and the clinical and 
microbiological parameters were assessed at baseline, 4 weeks and 6 months after 
treatment. The results showed that sonic scaler system and Scaling and Root 
Planning seem to provide similarly favourable periodontal healing results, although 
in deep pockets Scaling and Root Planning with hand instruments appeared to 
achieve a better resolution of inflammation. 
 Konopka L et al., (2012)[14] evaluated the effects of Scaling and Root 
Planing on levels of IL-1beta, IL-8 and MMP-8 in GCF in patients with periodontal 
disease. The results demonstrated that the short term non surgical therapy resulted in 
a significant improvement in periodontal indices and a marked decrease of IL-1beta, 
IL-8 and MMP-8 levels in gingival crevicular fluid. 
 Cabrera SM et al., (2015)[15] conducted a study to evaluate the effect of 
Scaling and Root Planing in Chronic Periodontitis patients by analyzing clinical, 
microbiological parameters and IL-1beta levels over a period of 12 months. The 
results demonstrated that there was a significant reduction of Porphyromonas 
gingivalis, Tanerella forsythia, Fusobacterium nucleatum and Aggregatibacter 
actinomycetemcomitans and this reduction was correlated with a decrease in clinical 
parameters as well as IL-1 beta reduction. 
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CYTOKINES 
 Cytokines act through receptors and are especially important in the immune 
system. Cytokines modulate the balance between humoral and cell-based immune 
responses and they regulate the maturation, growth, and responsiveness of particular 
cell populations. Some cytokines enhance or inhibit the action of other cytokines in 
complex ways. 
 Hansen HB et al., (1993)[16] demonstrated IL-1 as a powerful and potent 
bone resorbing cytokines. It has been found that IL-1α and IL-1β are equally 
important in stimulating bone resorption and probably exerts their effects on bone 
resorbing cells in several ways. It was shown that they stimulate the proliferation of 
precursor cells, but may also act indirectly on mature cells to stimulate bone 
resorption.  
 Faizuddin M et al., (2003)[17] evaluated the relationship between IL-1β 
levels in GCF and the inflammatory status of the periodontal tissues in the Indian 
population. Group 1 comprised of patients with clinically healthy gingiva with no 
loss of attachment. Group 2 comprised gingivitis patients with no attachment loss 
and Group 3 comprised gingivitis patients with attachment loss. The results 
demonstrated that the levels of IL-1β was significantly higher in group 3 compared 
to group 1 and group 2. 
SUPEROXIDE DISMUTASE  
 Sukhtankar L et al., (2013)[18] analyzed the effects of Non Surgical 
Periodontal Therapy on Superoxide Dismutase levels in gingival tissues of Chronic 
Periodontitis patients. The gingival tissues were collected and the Superoxide 
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Dismutase activity was assessed at baseline and at 2 months after Non Surgical 
Periodontal Therapy. The results showed that NSPT improved the clinical 
parameters and restored the previously increased SOD levels to normal in Chronic 
Periodontitis patients.  
 Biju T et al., (2014)[19] estimated and compared the Superoxide Dismutase 
and Glutathione levels in serum of patients with Chronic Periodontitis, gingivitis and 
healthy gingival before and after non surgical periodontal therapy. There was 
significantly higher levels of Superoxide Dismutase and Glutathione found in 
healthy group when compared to other groups. Also it was reported that the post 
treatment level of Superoxide Dismutase was higher than the pretreatment levels in 
periodontitis and gingivitis groups. 
SYSTEMIC DELIVERY OF ANTIBIOTICS 
 Systemic administration of antibiotics is a route of drug administration into 
the circulatory system so that the entire body is affected. Administration can take 
place via enteral administration (absorption of the drug through the gastrointestinal 
tract) or parenteral administration (generally injection, infusion, or implantation). 
 Kapoor A et al., (2012)[20] discussed the rationale, proper selection, dosage 
and the duration of the antibiotic therapy and mentioned about the various 
drawbacks of using systemic drug delivery. The drawbacks includes less blood 
concentration of the antibiotics, patient non compliance, antibiotic antagonism, 
inability of the antibiotic to penetrate to the site of infection, limited vascularity or 
decreased blood flow and unfavourable local factors such as decreased tissue pH or 
oxygen tension. 
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LOCAL DRUG DELIVERY 
 The local delivery of antimicrobial agents to periodontal pockets has the 
benefit of administering more drugs at the target site and the sustained release of 
antimicrobial in the periodontal pockets while minimizing the exposure of total body 
to the drug. 
 Several degradable and non-degradable devices are being used for the 
delivery of antimicrobial agents into the periodontal pocket including non-
biodegradable fibres, films, bio-absorbable dental materials, biodegradable gels/ 
ointments, injectables, microcapsules and bioadhesive delivery systems that could 
significantly improve oral therapeutics for periodontal disease and mucosal lesions. 
 Singh G et al., (2014)[21] highlighted the indications and advantages 
regarding the use of local drug delivery systems. The indications were deep pockets 
with very difficult access for Scaling and Root Planning, Refractory Periodontitis 
patients, deep pockets that failed to respond to Scaling and Root Planning and 
medically compromised patients where surgical therapy is contraindicated. The 
advantages includes effective concentration at the site of delivery is achieved as 100 
fold higher concentration is available at subgingival site when compared to systemic 
delivery. He also mentioned that superinfection and drug resistance are rare when 
drugs are given locally. 
 Ramesh A et al., (2016)[22] in a recent review discussed about various local 
drug delivery system and their effects. Based on the evidences, he indicated that 
Local Drug Delivery into periodontal pocket could improve the periodontal health. 
He also mentioned that controlled release properties can be applied as a therapeutic 
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component in the effective management of localized persisting lesion and the local 
drug administration should be based on patient clinical findings, scientific evidences 
and proper diagnosis.  
MOUTHWASH 
 Alshehri M et al., (2015)[23] evaluated the effects of Scaling and Root 
Planing with and without essential oil based mouthwash on IgG levels in patients 
with periodontal inflammation. One group of patients underwent Scaling Root 
Planing followed by a 10 ml rinse of essential oil based mouthwash for 30 days. The 
other group received Scaling and Root Planning alone. It was seen that Scaling and 
Root Planning when used along with essential oil based mouthwash was more 
effective in reducing whole salivary IgG levels as compared to Scaling and Root 
Planing alone. 
 Nadkerny PV et al., (2017)[24] assessed and compared the antiplaque and 
anti-inflammatory effects potential of a probiotic mouthwash with 0.2% 
chlorhexidine and saline. The results depicted that both probiotic and chlorhexidine 
mouthwash lead to reduction of plaque Index, Gingival Index and OHI-S 
significantly. He also demonstrated that these mouthwash can be successfully used 
in prevention of plaque and gingivitis as an adjunct to mechanical plaque control 
methods.    
FIBERS 
 Goodson JM et al., (1979)[25] tried to treat periodontal disease by placing 
drugs within the gingival sulcus. He used tetracycline filled hollow fibers in gingival 
sulcus and it had effect on both microbial count and clinical manifestation of the 
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disease. He also mentioned that 1/1000 of tetracycline needed for systemic therapy 
is sufficient for local delivery. He observed that elimination of spirochetes can be 
achieved by a single placement of tetracycline filled hollow fibers. 
 Grover HS et al., (2014)[26] compared two commercially available 
controlled release drugs – tetracycline fibers and chlorhexidine gel. Systemically 
healthy patients were chosen having Chronic Periodontitis. Three sites were 
involved having a probing depth of more than 6 mm. First site received tetracycline 
fibers, the second site with chlorhexidine gel and the third site was taken as a control 
with Scaling and Root Planing alone. The results demonstrated that there was 
statistically significant reduction in all clinical parameters such as Plaque Index, 
Bleeding Index, Probing pocket depth, Relative Attachment Level gain in 
tetracycline fibers and chlorhexidine gel site when compared to control site. 
 Polepalle T et al., (2017)[27] assessed the efficacy of local delivery of 
hyaluron 0.8% gel as an adjunct to Scaling and Root Planning in patients with 
Chronic Periodontitis. 0.2 ml hyaluron gel was placed subgingivally. Clinical 
parameters were assessed at 1st, 4th and 12th week. The results indicated that there 
was a significant reduction in Bleeding On Probing, Plaque Index, Probing Pocket 
Depth and Clinical Attachment Level in experimental site when compared to site 
that received Scaling and Root Planing alone. 
GEL FORM 
 Akncbay H et al., (2007)[28] used Chitosan, a novel biodegradable natural 
polymer, in a gel form (1%, w/w) with or without 15% metronidazole adjunctive to 
Scaling and Root Planing in patients with Chronic Periodontitis. The clinical 
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parameters were assessed at 6, 12 and 24 months. The end results indicated that 
metronidazole gel delivered through chitosan gel can be effectively used in the 
treatment of Chronic Periodontitis. 
STRIPS 
 Addy M et al., (1988)[29] evaluated the efficacy of chlorhexidine, 
Metronidazole and Tetracycline containing acrylic strips for the treatment of 
periodontal diseases. All the three antimicrobial agents differed on their action and 
spectra of activity. However all were found to have activity against many of the 
organisms considered pathogenic in periodontal diseases. Overall, the results 
demonstrated that subgingival antimicrobial drug in strip form have the potential 
value when used alone in treatment of Chronic Periodontal disease. 
 Takamori HYA et al., (1992)[30] developed a new controlled release film 
like strip containing Ofloxacin as an antibacterial agent. The drug was applied once 
a week for 4 weeks in periodontal pockets of Chronic Periodontitis patients. The 
results demonstrated that weekly application had a significant effect on the 
resolution of periodontal inflammation and has an inhibitory effect on supragingival 
plaque deposition. 
 Jeffcoat MK et al., (1998)[31] evaluated the efficacy of a controlled release 
biodegradable Chlorhexidine chip of 2.5 mg as an adjunct to Scaling and Root 
Planning. The chip released Chlorhexidine within the pocket over 7-10 days, 
maintaining an average concentration of Chlorhexidine in Gingival Crevicular Fluid 
greater than 125 microgram per ml for 8 days. At 9 months significant reductions 
from baseline clinical parameter value favouring the chlorhexidine chip compared 
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with both control treatments were observed with respect to probing depth and 
clinical attachment level. These datas demonstrate that the adjunctive use of the 
Chlorhexidine chip results in a significant reduction of Probing Depth when 
compared with both Scaling and Root Planing alone or the adjunctive use of a 
placebo chip. 
 Katiyar A et al., (2012)[32] conducted a study on periodontal film and 
demonstrated that the Lomefloxacin hydrochloride films can produce much higher 
levels of drug at the site of interest with no side effects in comparison to 
conventional oral therapy for prolonged periods.  
 Umadevi S et al., (2012)[33] demonstrated that Ciprofloxacin films had 
antibacterial activity on periodontal pathogens such as Porphyromonas gingivalis, 
Prevotella intermedia and Aggregatibacter actinomycetemcomitans at different 
concentrations. 
MICROCAPSULES 
 Yeom HR et al., (1997)[34] evaluated the clinical and microbiological 
efficacy of subgingival delivery of 10% minocycline loaded microcapsules in 15 
adult periodontitis patients. In the supragingival scaling + 10% Minocycline loaded 
group, spirochetes and motile rods decreased and the percent of cocci increased after 
1 week. The results demonstrated that 10% Minocycline loaded microcapsules can 
reduce Probing Depth and Bleeding on probing greater than Scaling and Root 
Planning and can induce microbial response more favourable for periodontal health.       
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NATURAL HERBS 
 Herbal and natural products have been used for centuries in every culture 
throughout the world.  Plants and natural products from time immemorial used for 
their pharmacological applications such as antiulcerogenic, wound healing, anti-
inflammatory, antimicrobial, antioxidant properties etc. 
 Bonjar S et al., (2004)[35] reported 45 species of plants from which 29 plant 
families were used in the traditional medicine by the Iranian people and they had 
antibacterial activities against one or more of the bacterial species. He also depicted 
that those plant extracts were able to overcome the disadvantages of antibiotics like 
drug resistance and undesirable side effects. 
 Kala BS et al., (2015)[36] summarized the effects of natural products like 
Acaciacatechu, Aloe vera, Azadirachata indica, Ocimum sanctum, Punica granatum 
and other important herbs to treat various periodontal diseases. He concluded that 
the antimicrobial activities of these herbal drugs can be potentially used against 
periodontal diseases. 
PUNICA GRANATUM  
 Tyagi S et al., (2012)[37] reported that punicalagins are tannins and are large 
phenolic compounds and are found in two forms α and β in pomegranates. He also 
mentioned that punicalagin represents major component responsible pomegranates 
antioxidant property. Punicalagins also have been shown to reduce cholesterol and 
lowers blood pressure and also have been reported to increase the speed at which 
heart blockages melts away. 
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 Howell AB et al., (2013)[38] reported that methanolic extracts of the fruit, 
especially of the peel exhibited the broadest antibacterial activity. The methanolic 
extracts of pomegranate were found to be rich in hydrolysable tannins (Punicalins 
and Punicalagins), ellagic acid, a component of ellagitannins and gallic acid. He also 
added that pomegranate possess positive effects on probiotic bacteria. 
 Rawahi AS et al., (2013)[39] reported that polyphenols are widely distributed 
among many plants and contains more than 8000 phenolic compounds. Polyphenols 
forms major component of pomegranate and are known for their antioxidants, anti-
inflammatory, antimutagenic, anticarcinogenic and antimicrobial property. He also 
reported that chromatographic analysis revealed the presence of over 61 total 
phenolic compounds which included Gallic acid, Ellagic acid, Punicalin, 
Punicallagin and Malic acid etc. 
 Sreekumar S et al., (2014)[40] in a review article has mentioned 
pomegranate extract as a rich source of biologically active compounds. The different 
parts of pomegranate plant like peel, root, bark, flower, leaves exhibited different 
phytochemicals. Punicalagin was found to be the main polyphenolic compound 
present in pomegranate peel. He also discussed about various therapeutic benefits 
and their mechanisms especially of antioxidants, anticarcinogenic and anti-
inflammatory properties. 
 Prasad D et al., (2014)[41] has depicted that pomegranate juice possesses 
anti-atherosclerotic, anti-hypertensive, anti-aging and antioxidant effect. He also 
reported that the antibacterial property of pomegranate was due to the presence of 
tannins which increased bacteriolysis and interferes with bacterial adherens 
mechanisms onto the tooth. Pomegranate, thereby could serve as an excellent 
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adjunct to the conventional periodontal therapy as an anti-plaque agent due to its 
antibacterial properties. 
 Masaud IA et al., (2014)[42] reported that the high antioxidant capacity of 
pomegranate is largely attributed to the polyphenol Ellagitannins (Punicalagins and 
Punicalins). In this review, the chemotherapeutic potential of fruit extract against 
breast cancer, prostate cancer and colon cancer were considered and dictated that the 
anticancerous effect is due to the antioxidant capacity of pomegranate. 
INVITRO STUDIES 
 Singh RP et al., (2002)[43] evaluated the efficacy of antioxidant rich fractions 
extracted from the peels and seeds of pomegranate. This was the first study on the 
antioxidant properties of extracts from pomegranate peel and seeds. The methanol 
extracts showed 56, 58 and 43.7 µg/ml inhibition using thiobarbituric acid method, 
hydroxyl radical scavenging activity and Low Density Lipoprotein oxidation 
respectively at 100 ppm. 
 Lee CJ et al., (2010)[44] evaluated 4 components of pomegranates for their 
anti-inflammatory property namely Punicalagin, Punicalin, Strictinin A and Granatin 
B. He demonstrated that all the four hydrolyzable tannins inhibited the NO 
production and iNOS expression in RAW 264.7 cells. The results suggested that all 
these 4 components can be used as a marker for anti-inflammatory effect of 
pomegranate. 
 Abdollahzadeh SH et al., (2011)[45] evaluated the effect of methanolic 
extract of Punica granatum peel against Streptococcus mutans, Staphylococcus 
aureus, Staphylococcus epidermis, Streptococcus salivarius, Lactobacillus 
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acidophilus and Candida albicans. Methanolic extract of Punica granatum peel were 
used at a concentration of 4mg/ml, 8mg/ml and 12mg/ml. The activity was evaluated 
by agar disk diffusion method. The results showed that all the concentrations 
inhibited the Staphylococcus epidermis and Staphylococcus aureus. 8mg/ml and 12 
mg/ml were effective against Lactobacillus acidophilus, Streptococcus mutans and 
Steptococcus salivarius. The results suggested that pomegranate extract can be used 
as an antibacterial agent in controlling oral infections. 
 Xu X et al., (2014)[46] evaluated the mechanism behind the anti-
inflammatory potential of punicalagin in LPS induced macrophages. The results 
indicated that PUN at concentrations of 25, 50 or 100 µM could significantly 
decrease the LPS induced NO, PGE2,  IL-1β, IL-6 and TNF-α in RAW 264.7 cells. 
Molecular research indicated that these effect were due to inhibition of NF-țβ via 
Ițβα and p-65 supression. The results concluded that Punicalagin can be a potential 
choice for the treatment of inflammatory diseases. 
 Aloqbi A et al., (2016)[47] evaluated the antioxidant activities of punicalagin 
and pomegranate juice. The antioxidant mechanisms included were DPPH radical 
scavenging activity, Hydrogen peroxide scavenging, Ferrous chelating and reducing 
ability. The results showed that punicalagin showed significant Ferrous chelating 
activity and reducing power ability in a dose dependent manner when compared to 
pomegranate juice. 
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INVIVO STUDIES 
 Murthy KNC et al., (2002)[48] tried to evaluate the antioxidant efficacy of 
methanolic extract of pomegranate on Catalase, Peroxidase and Superoxide 
Dismutase enzyme levels. He administered 50 mg/ml of methanolic extract of 
pomegranate followed by 2.08/kg of Ccl4. Histopathological studies showed 
hepatoprotective effect of methanolic extract against Ccl4. The results also showed 
that all the three antioxidant enzyme levels were preserved by the methanolic 
extracts. 
 Cerda B et al., (2003)[49] indicated the effects of punicalagins in rats and 
evaluated its possible toxic effect in Sprague – Dawley rats upon repeated oral 
administration of a 6% punicalagins containing diet for 37 days. The results reported 
that the high dose of punicalagin was non toxic to rats when administered even for 
37 days. 
 Sastravaha et al., (2005)[50] evaluated the efficacy of combined herbal 
preparation in comparison to a standard Supportive Periodontal Therapy. Patients 
having Probing Pocket Depth of 5-8 mm after Conventional Periodontal Therapy 
were selected and given a medicated chip consisting of Centella asiatica and Punica 
granatum. The result showed improvement of Probing Depth, Attachment level, 
Gingival Index at 3 and 6 months and Bleeding Index at 6 months in test group 
compared to control group. Also the IL-1 level was significantly decreased in the 
test group. 
 Disilvestro RA et al., (2009)[51] compared the efficacy of pomegranate 
mouthwash against a placebo of cornstarch in water. It was a 4 week study in which 
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study population were advised to rinse the mouth with prescribed mouthwash thrice 
a day. The result demonstrated a reduction in total protein concentration, aspartate 
aminotransferase, alpha glucoside activity, increased antioxidant enzyme 
cerruloplasmin and increased radical scavenging activity. From the results it was 
concluded that pomegranate extracts can be included in oral health products. 
 Larrosa et al., (2009)[52] evaluated the beneficial effect of pomegranate 
against inflammatory markers. Male fischer rats were fed with 250mg/kg/day 
pomegranate extract. He noted that pomegranate extract decreased the inflammatory 
markers like iNOS, COX 2, PGE2 in colonic mucosa and also modulated favourably 
the gut microbiota. 
 Bhadbhade SJ et al., (2011)[53] evaluated the antiplaque efficacy of 
pomegranate containing mouthwash. Patients were randomly divided into 3 groups 
and were given pomegranate, chlorhexidine and distilled water mouthwashes twice 
daily. Microbiological evaluation included Actinobacillus actinomycetemcomitans, 
Porphyromonas gingivallis and Prevotella intermedia. The results indicated 
reduction of Plaque index in all the three groups and reported that pomegranate 
mouthwash showed an increased antiplaque effect and was effective against 
Actinobacillus actinomycetemcomitans, Porphyromonas gingivallis and Prevotella 
intermedia at concentrations of 62.5mg/ml, 31.25mg/ml and 16.125mg/ml 
respectively. 
 Gomes et al., (2016)[54] evaluated the antibacterial effect of punica granatum 
extract against the periodontal pathogen P.gingivalis by using Galleria mellonella as 
an invivo model. Results showed that Punica granatum extract had antibacterial 
activity against P.gingivalis at all concentrations of 12.5, 6.25, 3.1 and 2.5 mg/ml 
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used in this study. The results also demonstrated that pomegranate extract can be 
used against periodontal pathogens. 
Umar D et al., (2016)[55] evaluated the influence of pomegranate extract 
mouthrinse on salivary pH and the levels of Streptococcus mutans. The results 
showed a significant reduction in the Streptococcus mutans count on usage of 
pomegranate extract mouth rinse. Therefore the present study implies that 
pomegranate extract can be used to maintain good oral hygiene and as an 
antibacterial compound. 
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A randomized controlled, split mouth clinical study was conducted to 
evaluate the effectiveness of subgingival application of punicalagin gelatin film as 
an adjunct to Scaling and Root Planning compared with scaling and root planning 
alone in patients with chronic periodontitis. The protocol was reviewed and 
approved by institutional ethical board. The study related procedures were explained 
to the patients before they sign an informed consent form. A total of 30 subjects 
each with bilateral 5-6 mm probing pocket depth (PPD) were recruited from the 
outpatient in Department of Periodontics, J.K.K. Nattraja Dental College and 
Hospitals, Kumarapalayam, Tamilnadu. 
Inclusion criteria 
1. Patient age group of 20-50 years with generalised chronic periodontitis  
2. Minimum of 20 teeth to be present in every patient 
3. Minimum of 2 sites with more than 5mm of pocket depth as assessed by 
Williams periodontal probe 
4. Minimum of 6 sites which shows bleeding on probing  
Exclusion criteria 
1. Patients suffering from known systemic diseases 
2. Patients who are pregnant and lactating 
3. Patients who are smokers and alcoholics 
4. Patients who received any chemotherapeutic mouth rinse or oral irrigation 
during past 6 months 
5. Patients who received surgical or non surgical therapy in last 6 months 
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6. Patients with Aggressive Periodontitis 
7. Patients who received any antibiotic therapy in the last 6 months 
STUDY DESIGN 
A split mouth design was followed, where two sites with probing pocket 
depth of 5-6 mm were chosen. Probing Pocket Depth standardization was done with 
acrylic stent in all the selected areas. 
CRITERIA FOR GROUPING 
Selected sites were randomly divided into control sites and experimental sites as 
follows 
 Group I - It consists of 30 sites, in which Scaling and Root Planning (SRP) was 
done (control sites). 
 Group II - It consists of 30 sites, in which scaling and root planning was 
followed by the placement of the punicalagin gelatin film inside the pocket (SRP 
+ Punicalagin gelatin film) (Test sites). 
CLINICAL PARAMETERS 
The following variables were measured at baseline and at 21 days 
 Plaque index (PI) (Silness and Loe 1964) 
 Gingival index (GI) (Loe and Silness 1963) 
 Sulcus Bleeding Index (SBI) (Muhlemann HR and Sen S 1971)  
 Probing Pocket Depth (PPD) 
 Clinical attachment level (CAL) 
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1. Plaque index (Silness and Loe 1964) 
The four gingival areas of the tooth surfaces examined are the disto-facial, 
facial, mesio-facial and lingual surfaces. 
Scoring was as follows:  
0 – No plaque. 
1 – A film of plaque adhering to the free gingival margin and adjacent area of the 
tooth. The plaque may be seen only by running a probe across the tooth surface. 
2 – Moderate accumulation of soft deposits within the gingival pocket, on the 
gingival margin and/or adjacent tooth surface, which can be seen by the naked eye.  
3 – Abundance of soft matter within the gingival pocket and/or on the gingival 
margin and adjacent tooth surface.  
The scores of the four areas of the tooth can be summed and divided by four 
to give the PI for the tooth. A score from  
0.1– 0.9 – Good. 
1.0 – 1.9 – Fair. 
2.0– 3.0 – Poor 
2. Gingival index (Loe and Silness 1963) 
The Gingival index was created to assess the severity of gingivitis based on 
its color, consisitency and bleeding on probing. The tissues surrounding each tooth 
are divided into four gingival scoring units: Distal facial papillae, Facial margin, 
Mesial facial papillae, Entire lingual gingival margin. 
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The criteria are 
0 – Normal gingiva 
1 – Mild inflammation – slight change in color and slight oedema but no bleeding on 
probing. 
2 – Moderate inflammation – redness, oedema and bleeding on probing. 
3 – Severe inflammation – marked redness and oedema, ulceration with tendency to 
spontaneous bleeding. 
The scores of four areas of the tooth can be summed and divided by four to give the 
GI for the tooth. A score from. 
0.1– 1.0 – Mild inflammation 
1.1– 2.0 – Moderate inflammation 
     2.1 – 3.0 – Severe inflammation 
3. Sulcus Bleeding Index (SBI) (Muhlemann HR and Sen S 1971) 
An early sign of gingivitis is bleeding on probing and, in 1971, Muhlemann and Son 
described the Sulcus Bleeding Index (SBI). The criteria for scoring are as follows: 
Score 0 – health looking papillary and marginal gingiva no bleeding on probing; 
Score 1 – healthy looking gingiva, bleeding on probing; 
Score 2 – bleeding on probing, change in color, no edema; 
Score 3 – bleeding on probing, change in color, slight edema; 
Score 4 –bleeding on probing, change in color, obvious edema; 
Score 5 –spontaneous bleeding, change in color, marked edema. 
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 Four gingival units are scored systematically for each tooth: the labial and 
lingual marginal gingival (M units) and the mesial and distal papillary gingival (P 
units). Scores for these units are added and divided by four. Adding the scores of the 
undivided teeth and dividing them by the number of teeth can determine the sulcus 
bleeding index. 
 The least score is 0. The maximum score is 320. 
4. Probing pocket depth (PPD) was recorded by selected sites using 
William’s graduated periodontal probe. The probe was inserted parallel to the long 
axis of the tooth gently, until resistance was felt and the readings were recorded to 
the nearest millimeter from the gingival margin to the base of the pocket. Acrylic 
stents were used to standardize the path of insertion and angulations of the probe. 
5. Clinical attachment level (CAL) - Distance between the base of the 
pocket and Cementoenamel Junction (CEJ) or a fixed reference point. The distance 
from the CEJ (if CEJ not detected, the coronal border of the stent was used) to the 
base of the pocket was measured.The readings were recorded to the nearest 
millimeter. 
INVITRO STUDIES 
Preparation of Test Organism  
Preparation of standard bacterial suspensions  
The average number of viable, Gram negative Porphyromonas gingivalis 
organisms per ml of the stock suspensions was determined by means of the surface 
viable counting technique (Miles and Misra, 1938). About (105-106) colony-forming 
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units per ml was used. Each time, a fresh stock suspension was prepared; the 
experimental conditions were maintained constant so that suspensions with very 
close viable counts would be obtained.  
Antibacterial Activity Screening  
Determination of the Minimal Inhibitory Concentrations (MIC)  
MIC was determined with 96-well plate microdilution method. Briefly, the 
bacterial strain was grown for 24 h anaerobically and inoculated into a final volume 
of 100 ȝL of new half-strength BHI broth containing 2-fold serial dilutions of 
samples. The final optical density of the bacterial cells was adjusted to 0.1 at 600 nm 
in 100 ȝL of mixture. The mixture was cultured anaerobically at 37 °C for 48 hour. 
The bacterial growth was measured at an optical density of 600 nm. The lowest 
concentration at which no growth (OD 600nm ≤ 0.1) was observed was defined as 
MIC (ȝg/mL). The concentrations of the sample used for MIC were between 100-
7.25 ȝg/mL.  
Preparation of PC periodontal films 
Materials : Punicalagin (PC), Carbosynth Ltd, United Kingdom. Gelatin, Sterling 
Biotech Limited, Tamilnadu, India. Glycerine and Triethanolamine SD Fine 
chemicals, Mumbai, India. Sorenson's phosphate buffer pH 6.6 
Methods : 
 Film formulations were prepared using the solvent casting technique (Table 
1). Gelatin solution (20%) was prepared by dissolving gelatin in Millipore water. 1% 
v/v glycerol, which was used as a plasticizer to impart adequate flexibility to the 
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produced films. Calculated amount of PC (10mg/film) was added to the final gel 
before casting. The pH of gel formulation was adjusted to about neutrality (pH 6) by 
the addition of triethanolamine (0.3%) before casting. The medicated gels were left 
overnight at room temperature to get rid of any bubbles formed while stirring. The 
gels were casted into square cube trays and allowed to dry in a levelled oven 
maintained at 30oC, for a period of time enough to produce flexible, dry film with 
constant weight. The dried films were cut into rectangular (5X2 mm) patches, 
packed in aluminum foil and stored in desicator which was maintained at room 
temperature. 
Composition of PC periodontal films 
Composition Concentration (%) 
PC 10mg/film 
Gelatin 20 
Glycerine 3 
Triethanolamine 0.3 
Physical characterization and content uniformity test 
 Assessment of weight and thickness was done on six randomly chosen film 
patches from each formulation using a sensitive balance (Electronic balance, 
Sartorius AG, weighting technology, BL-210S, Germany) and a digital micrometer 
(Tricircle micrometer, China), respectively. Determinations were performed in 
triplicate. Drug content uniformity was tested on six randomly selected film patches 
of each formulation. Each drug-loaded patch was allowed to dissolve in 100 ml of 
Sorenson's phosphate buffer pH 6.6. The concentration of PC in the patch was 
determined spectrophotometrically at 378 nm. UV standard curves were constructed 
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over a concentration range of 5-25 mg/ml. All results are presented as mean ± 
standard deviation. 
Surface pH 
 Film patches were allowed to swell for 2 hr on the surface of agar plates 
prepared in Sorenson's phosphate buffer pH 6.6. The surface pH was determined 
using pH paper placed on the surface of the swollen patch. A mean of three readings 
were recorded. 
In vitro release study 
 Each disc (5X2 mm) was weighed and placed into a 5 ml vial containing 2 
ml Sorenson buffer of pH 6.6, previously warmed at 37oC. The closed vials were 
placed in a thermostatically controlled water bath preset at 37oC, until the end of the 
experiment. The whole volume was withdrawn at predetermined time intervals (0.5, 
1, 2, 3, 4, 6, 8, 24, 48 and 72 h) and replaced by fresh warmed buffer solution. The 
samples were assayed for PC spectrophotometrically at Ȝmax 378 nm, and the 
cumulative drug concentrations were calculated. All experiments were done in 
triplicate and the values were presented as the mean ± standard deviation. Blank 
films were also subjected to the release study to detect the contribution of the 
polymers used, if any, to UV absorption. 
Calibration curve 
 From 100 mg/mL of stock solution a series of dilutions ranging from 5 - 25 
mg/ml was prepared. The sample was analysed through UV-Vis spectrophotometer 
at a Ȝ max of 378 nm and the calibration curve was plotted.  
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In vitro release study 
 A burst release of PC from both types of films was observed throughout the 
first 2 hr. This effect was followed by a decrease in the release rate for the next 10 h, 
then by a marked decrease in rate to the end of the study. Release of PC from gelatin 
films was performed in 2 ml buffered system at pH 6.6 to simulate the small space 
available of the periodontal cavity, the un-sink condition and pH. The initial burst 
release effect observed from all films could be explained by the fact that the drug 
may exist in the finely divided state after solvent evaporation during film casting and 
their deposition on the surface of the films after drying. Two main targets are to be 
achieved when inserting a medicated film in the periodontal pocket, to release an 
initial high dose of drug in order to produce an immediate therapeutic effect, 
followed by small doses to maintain the therapeutic level throughout a longer period 
of time. The general initial increase of the dissolution of PC from gelatin films could 
also be attributed to the presence of the water-soluble gelatin and also water-soluble 
hydrophilic additives in these films that would dissolve rapidly introducing porosity. 
The formed voids will in turn allow for the entrance of the release media and its 
diffusion through the film. 
BIO-CHEMICAL PARAMETERS 
Collection of preoperative GCF 
 The test and control sites were isolated by cotton rolls and gently air-dried to 
remove saliva. Before gingival crevicular fluid collection supragingival plaque was 
removed. A 2 µL sterile glass microcapillary tube was placed at the opening of the 
periodontal pocket and left for 30 seconds to draw 0.25 µL of gingival crevicular 
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fluid (draw 4 mm along 32 mm tube, holding maximum volume of 2 µL) into the 
microcapillary tube.  
 The sample was discarded if blood was detected within the microcapillary 
tube. Each gingival crevicular fluid sample was immediately placed into a sterile, 
labeled Eppendorf tube and placed on ice then transported to the laboratory for 
processing.  
Non-Surgical Periodontal Therapy 
 At baseline full mouth ultrasonic scaling was done. Under local anesthesia 
with 2% lignocaine solution (1:80,000), root planning was done in the test and 
control sites using area-specific double-ended Gracey curettes (Hu-Friedy). The test 
site was isolated with cotton rolls to prevent contamination with saliva. The 
Punicalagin gel was carried with a tweezer and placed in the periodontal pocket. The 
pocket opening was covered with Coe-Pak to retain the material in the pocket, as 
well as to prevent the ingress of oral fluids.         
          Oral hygiene maintenance instructions were given as in Appendix I.  Subjects 
were recalled at 7th and 14th day for application of punicalagin gelatin film and after 
21 days post operative GCF samples were collected. Clinical parameters were 
repeated after 21 days. 
Determination of IL-1β level in GCF using ELISA 
 Level of IL-1β in the GCF was assayed by using commercially available 
Human IL-1 beta ELISA reagent set (e-Bioscience).      
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Description 
 This Human IL-1 beta ELISA reagent set (with or without high-affinity 
binding microwell plates) contains the necessary reagents, buffers and diluents for 
performing quantitative enzyme linked immune sorbent assays (ELISA). This 
ELISA reagent set is specifically engineered for accurate and precise measurement 
of human IL-1 beta protein levels from samples including serum, plasma, and 
supernatants from cell cultures. This ELISA will recognize the cleaved mature form 
and uncleaved pro-form of Human IL-1 beta.  
Reagents used 
 Capture Antibody: Pre-titrated, purified antibody.  
 Detection Antibody: Pre-titrated, biotin-conjugated antibody.  
 Standard Recombinant cytokine for generating standard curve and 
calibrating samples  
 ELISA/ELISPOT Coating Buffer Powder: This ELISA Set may contain 
ELISA/ELISPOT Coating Buffer Powder (Reconstitute to 1L with dH20 and 
filter (0.22 uM)) or 10X PBS ELISA Coating Buffer (Dilute 1 part 10X 
Buffer into 9 parts dH20).  
 Assay Diluent: 5X concentrated  
 Detection enzyme: Pre-titrated Avidin-HRP  
 Substrate Solution: Tetramethylbenzidine (TMB) Substrate Solution  
 96 Well Plates 
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Experimental Procedure  
 Coat Corning Costar 9018 (or Nunc Maxisorp) ELISA plate with 100 
ȝL/well of capture antibody in Coating Buffer (dilute as noted on C of A, which is 
included with the reagent set). Seal the plate and incubate overnight at 4°C.  
Aspirate wells and wash 3 times with >250 ȝL/well Wash Buffer. Allowing time for 
soaking (~ 1 minute) during each wash step increases the effectiveness of the 
washes. Blot plate on absorbent paper to remove any residual buffer.  
 Dilute 1 part 5X concentrated Assay Diluent with 4 parts DI water. Block 
wells with 200 ȝL/well of 1X Assay Diluent. Incubate at room temperature for 1 
hour wells. Perform 2-fold serial dilutions of the top standards to make the standard 
curve for a total of 8 points. Add 100 ȝL/well of your samples to the appropriate 
wells. Seal the plate and incubate at room temperature for 2 hours (or overnight at 
4°C for maximal sensitivity). 
 Aspirate/wash as in step 2. Repeat for a total of 3-5 washes. Add 100 
ȝL/well of detection antibody diluted in 1X Assay Diluent. Seal the plate and 
incubate at room temperature for 1 hour. Aspirate/wash as in step 2. Repeat for a 
total of 3-5 washes. Add 100 ȝL/well of Avidin-HRP diluted in 1X Assay Diluent. 
Seal the plate and incubate at room temperature for 30 minutes. 
 Aspirate and wash as in step 2. In this wash step, soak wells in Wash Buffer 
for 1 to 2 minutes prior to aspiration. Repeat for a total of 5-7 washes. Add 100 
ȝL/well of Substrate Solution to each well. Incubate plate at room temperature for 
15 minutes. 
 Add 50 ȝL of Stop Solution to each well. Read plate at 450 nm. If 
wavelength subtraction is available, subtract the values of 570 nm from those of 450 
nm and analyze data. 
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Interpretation of Results 
 Sample results were expressed as pg/mL and do not need to be corrected for 
dilution (unless sample was diluted prior to testing). 
ENZYME LINKED IMMUNOSORBENT ASSAY: 
The kit is a sandwich enzyme immunoassay for in vitro quantitative 
measurement of superoxide dismutase in human serum, plasma, tissue homogenates, 
cell lysates and other biological fluids. An anti-human SOD coating antibody is 
adsorbed onto microwells. Human SOD present in the sample or standard binds to 
antibodies adsorbed to the microwells. A HRP-conjugated anti-human SOD 
antibody is added and binds to human SOD captured by the first antibody. 
Following  incubation unbound  HRP- conjugated  anti-human SOD is removed 
during a wash step, and substrate solution reactive with HRP is added to the wells. A 
coloured product is formed in proportion to the amount of human SOD present in 
the sample or standard. The reaction is terminated by addition of acid and 
absorbance is measured at 450 nm. A standard curve is prepared from 7 human SOD 
standard dilutions and human SOD concentration determined.  
REAGENTS PROVIDED WITH KIT 
 Reagents for human SOD ELISA ALX-850-033  
a) 1 Aluminium pouch with a Microwell Plate coated with monoclonal 
antibody to human SOD. 
b) 1 Vials (20 µl) HRP-Conjugate anti-human SOD monoclonal antibody  
c) 2 vials (500 µl) human SOD Standard, 5 ng/ml 
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d)  1 vial (5 ml) Assay Buffer Concentrate 20x (PBS with 1% Tween 20 
and 10% BSA) 
e)  1 vial (5 ml) Phosphate Buffered Saline Concentrate (PBS) 20x  
f) 1 bottle (50 ml) Wash Buffer Concentrate 20x (PBS with 1% Tween 20)  
g) 1 vial (15 ml) Substrate Solution (tetramethyl - benzidine)  
h) 1 vial (15 ml) Stop Solution (1M Phosphoric acid)  
i) 1 vial (0.4 ml) Blue-Dye  
j) 1 vial (0.4 ml) Green-Dye  
k) 2 Adhesive Films  
MATERIALS REQUIRED BUT NOT AVAILABLE WITH THE KIT: 
1. 5 ml and 10 ml graduated pipettes  
2. 5 µl to 1000 µl adjustable single channel micropipettes with disposable 
tips  
3. 50 µl to 300 µl adjustable multichannel micropipette with disposable tips  
4. Multichannel micropipette reservoir  
5. Beakers, flasks, cylinders necessary for preparation of reagents  
6. Device for delivery of wash solution (multichannel wash bottle or 
automatic wash system)  
7. Microwell strip reader capable of reading at 450 nm (620 nm as optional 
reference wave length)  
8. Glass-distilled or deionized water  
9. Statistical calculator with program to perform regression analysis  
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ASSAY PROCEDURE: 
Determine the number of microwell strips required to test the desired number 
of samples plus appropriate number of wells needed for running blanks and 
standards. Each sample, standard, blank and optional control sample should be 
assayed in duplicate. Remove extra microwell strips from holder and store in foil 
bag with the desiccant provided at 2°-8°C sealed tightly.  
Wash the microwell strips twice with approximately 400 µl WashBuffer per 
well with thorough aspiration of microwell contents between washes. Allow the 
Wash Buffer to sit in the wells for about 10 – 15 seconds before aspiration. Take 
care not to scratch the surface of the microwells. After the last wash step, empty 
wells and tap microwell strips on absorbent pad or paper towel to remove excess 
Wash Buffer. Use the microwell strips immediately after washing. Alternatively 
microwell strips can be placed upside down on a wet absorbent paper for not longer 
than 15 minutes. Do not allow wells to dry.   
Add 100 µl of PBS (1x) in duplicate to standard wells B1/2- G1/2, leaving 
A1/A2 empty. Pipette 200 µl of undiluted standard (concentration = 5.00 ng/ml) in 
duplicate into well A1 and A2. Transfer 100 µl to wells B1 and B2. Mix the contents 
of wells B1 and B2 by repeated aspiration and ejection, and transfer 100 µl to wells 
C1 and C2, respectively. Take care not to scratch the inner surface of the 
microwells. Continue this procedure 4 times, creating two rows of humanSOD 
standard dilutions ranging from 5.00 to 0.08 ng/ml. Discard 100 µl of the contents 
from the last. 
Add 100 µl of PBS (1x)in duplicate to the blank wells.  
Add 90 µl of PBS (1x)to the sample wells.  
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Add 10 µl of each prediluted sample in duplicate to the sample wells.  
Prepare HRP-Conjugate.  
Add 50 µl of HRP-Conjugate to all wells.  
Cover with an adhesive film and incubate at room temperature (18 to 25°C) 
for 1 hour, if available on a microplate shaker set at 100 rpm.  
Remove adhesive film and empty wells. Wash microwell strips 3 times 
according to point 0. of the test protocol. Proceed immediately to the next step.  
Pipette 100 µl of TMB Substrate Solution to all wells.  
Incubate the microwell strips at room temperature (18° to 25°C) for about 10 
min. Avoid direct exposure to intense light.  
The colour development on the plate should be monitored and the substrate 
reaction stopped before positive wells are no longer properly recordable. 
Determination of the ideal time period for colour development has to be done 
individually for each assay.  
It is recommended to add the stop solution when the highest standard has 
developed a dark blue colour. Alternatively the colour development can be 
monitored by the ELISA reader at 620 nm. The substrate reaction should be 
stopped as soon as Standard 1 has reached an OD of 0.9 – 0.95.  
Stop the enzyme reaction by quickly pipetting 100 µl of Stop Solution into 
each well. It is important that the Stop Solution is spread quickly and uniformly 
throughout the microwells to completely inactivate the enzyme. Results must be 
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read immediately after the Stop Solution is added or within one hour if the 
microwell strips are stored at 2-8°c in the dark. 
Read absorbance of each microwell on a spectrophotometer using 450 nm as 
the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 
650 nm is acceptable). Blank the plate reader according to the manufacturer's 
instructions by using the blank wells. Determine the absorbance of both the samples 
and the standards.  
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APPENDIX-1 
 POST THERAPY INSTRUCTIONS 
 Report immediately on development of any untoward reactions like pain, 
swelling, bleeding and drug allergies. 
 Avoid intake of any hard and hot foods, not to disturb the operated area with 
tongue. 
 Report if dressing is dislodged. 
 Avoid brushing the treated area from the day of therapy. Use cotton 
applicator to gently clean the area and resume gentle brushing with soft 
brush. 
 Avoid the use of medications and mouthrinses. 
 Follow up visits have to be done in 7th day, 14th day and 21st days .  
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             APPENDIX - 2 
PROFORMA                                                    
NAME:                                                                                                       O.P 
NUMBER: 
AGE:                                                                                                           DATE: 
SEX:                                                                                                            CASE 
NO: 
ADDRESS:                                                                                                 
OCCUPATION: 
CHIEF COMPLAINT: 
 
 DENTAL HISTORY: 
 
MEDICAL HISTORY: 
 
PERSONAL HISTORY: 
 
TEST SITE : 
CONTROL SITE: 
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CLINICAL PARAMETERS 
AT BASELINE 
PLAQUE  INDEX
 
Score 
Interpretation 
 
GINGIVAL INDEX
 
Score 
Interpretation 
 
SULCUS  BLEEDING INDEX
 
Score: 
Interpretation: 
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PROBING POCKET DEPTH( mm) 
 
 CLINICAL ATTACHMENT LEVEL(mm ) 
 
 
AT 3 WEEKS 
PLAQUE  INDEX
 
Score 
Interpretation 
GINGIVAL INDEX
 
Score 
Interpretation 
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SULCUS  BLEEDING INDEX
 
Score: 
Interpretation: 
PROBING POCKET DEPTH( mm) 
 
 CLINICAL ATTACHMENT LEVEL(mm ) 
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J.K.K. NATTRAJA DENTAL COLLEGE, KOMARAPALAYAM 
DEPARTMENT OF PERIODONTICS 
INFORMED CONSENT OBTAINED FROM THE PATIENT 
 
PATIENT NAME:  __________________________________________ 
 
 I have been explained about the nature and purpose of the study in which, I 
have been asked to participate. I understand that I am free to withdraw my consent 
and discontinue at any time without prejudice to me or effect on my treatment.  
  I have been given the opportunity to question about the material and study. I 
have also given the consent for photographs to be taken at the beginning, during and 
end of the study. I agree to participate in this study.  
 I hereby give the consent to be included in this study.   
 
 
Place:                                                                                                               
Date:                                                                                          Signature of Patient 
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APPENDIX – 3 
ARMAMENTARIUM 
MATERIALS AND INSTRUMENTS USED FOR THE STUDY 
 Gloves 
 Mouth mask 
 Patient apron 
 Chair apron 
 Head cap 
 Sterile cotton rolls 
 Gauze 
 Saline 
 Kidney tray 
 Betadine 
 Lignocaine 
 Syringe 
 Mouth mirror 
 Straight probe 
 Explorer 
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 Williams periodontal probe 
 Tweezer 
 Tissue holding forceps 
 Hu-Friedy Gracey Curettes 
 Microcapillary pipettes 
 Eppendorf tubes  
 Phosphate buffered saline 
 Punicalagin gelatin film 
 Scissor 
 Coe pak 
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URGICAL INSTRUMENTS 
 
 
MICROCAPILLARY PIPETTES, EPPENDORF TUBES 
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PUNICALAGIN POWDER 
 
 
PUNICALAGIN GELATIN FILM 
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CLINICAL CASES 
PRE-OPERATIVE 
               CONTROL GROUP                  TEST GROUP 
           
      GCF SAMPLE COLLECTION                      PLAQUE SAMPLE COLLECTION                              
           
 
SRP (SCALING AND ROOT PLANING) 
             CONTROL GROUP               TEST GROUP 
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TEST GROUP 
            SRP +  PUNICALAGIN            COE PACK 
          GELATIN FILM PLACED                                         PLACEMENT 
                    
 
 
POST OPERATIVE (21 DAYS) 
                CONTROL GROUP                                                TEST GROUP 
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CUMULATIVE RELEASE PROFILE OF PC FROM GELATIN IN  
BUFFER PH 6.6. 
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LAB ANALYSIS 
 
 
ELISA KIT  
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STATISTICAL ANALYSIS 
 The results obtained were analyzed statistically and comparisons were made 
between groups using Paired samples t test. ‘p value’ between Group I and Group II 
post-operatively were evaluated. p<0.001 denoted statistically significant and also 
denotes less than one in a thousand chance of being wrong. p<0.05 denotes that there is 
only 5% chance that the null hypothesis is true. The statistical analysis was done using 
SPSS software Version 19. 
Clinical evaluation 
 A total of 30 subjects were selected for the study and were divided in a split 
mouth design. Group I subjects were treated with SRP alone, whereas in Group II 
subjects local delivery of punicalagin gel along with SRP was done. No patient 
reported any discomfort or adverse reaction. 
Plaque index (PI) 
 The mean Plaque Index score at baseline was found to be 2.37 ± 0.62. After 21 
days of treatment the value was reduced to 1.39 ± 0.58 as shown in table 3 and graph 
4. Statistically significant difference was found from baseline to 21 days post-
treatment (p<0.001). 
Gingival Index (GI) 
At baseline, the mean Gingival Index score was 2.53 ± 0.67, and was 
reduced to 1.43 ± 0.52 after 21 days post-treatment as shown in table 3 and graph 4. 
There was statistically significant reduction in gingival index after 21 days post-
treatment (p<0.001). 
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Sulcus Bleeding Index (SBI) 
 SBI at baseline was 2.75 ± 0.28 and was decreased to 1.75 ± 0.29 after 21 
days post-therapy as shown in table 3 and graph 4. There was statistically significant 
decrease in bleeding after 21 days post-therapy (p<0.001). 
Probing pocket depth (PPD) 
In Group I the mean PPD at baseline was 5.69 ± 0.00 mm and after 21 days 
of post-treatment the value reduced to 2.92 ± 0.17 mm. In Group II, at baseline the 
mean PPD was 5.74 ± 0.00 mm, and at 21 days reduced to 2.05 ± 0.62 mm as shown 
in table 4 and graph 5. There was statistically significant reduction in PPD after 21 
days post-therapy in both groups (p<0.001). Group II showed more statistically 
significant reduction in PPD at 21 days post-therapy, compared to group I (p<0.001) 
as shown in table and graph. 15.6% more reduction of PPD was seen in group II 
(64.3%) when compared to group I (48.7%) as shown in table 5 and graph 7.  
Clinical Attachment Level 
In Group I, at baseline the mean CAL was 3.69 ± 0.22 mm and at 21 days 
reduced to 1.82 ± 0.48 mm. In Group II, at baseline the mean CAL was 3.74 ± 0.38 
mm and at 21 days reduced to 0.82 ± 0.22 mm as shown in table 6 and graph 6. 
There was statistically significant gain in CAL after 21 days post-therapy in group II 
(p<0.001). Group II showed more statistically significant gain in CAL at 21 days 
post-therapy, compared to group I (p<0.001) as shown in table 6 and graph 6. 27.6% 
more gain in CAL was seen in group II (79.1%) when compared to group I (51.5%) 
as shown in table 7 and graph 8.  
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IL-1β level in GCF  
At baseline, the mean level of IL-1β in GCF in Group I was 78.23 ± 0.36 
pg/ml and decreased to 59.53 ± 0.22 pg/mL 21 days after therapy. In Group II, the 
baseline value was 79.36 ± 0.18 pg/ml and decreased to 37.9 ± 0.83 pg/ml after 21 
days post-therapy as shown in table 8.  There was statistically significant decrease in 
the level of IL-1β after 21 days post-therapy in both the groups (p<0.001). When 
comparing both the groups, Group II has more statistically significant (p<0.05) 
decrease in the level of IL-1β than Group I post-therapy as shown in graph 9. 
SOD Levels 
 In Group I, at baseline the superoxide dismutase levels were 111.83 ± 0.97 
U/0.5ml and 21 days after treatment SOD levels improved to 189.73 ± 0.27 U/0.5ml. 
Comparison of SOD levels at baseline and after treatment shows a statistically 
significant difference with p<0.05. In Group II, the superoxide dismutase levels at 
baseline was 124.56 ± 0.74 U/0.5ml and 21 days after treatment SOD levels 
improved to 263.36 ± 0.23 U/0.5ml. Comparison of SOD levels at baseline and after 
treatment shows that there is a statistically significant difference with p<0.05. When 
comparing both the groups, Group II has more statistically significant (p<0.05 ) 
increase in the level of  SOD than Group I after 21 days post-therapy as shown in 
table 9  and graph 10. 
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TABLE 1 : Composition of PC periodontal films 
Composition Concentration (%) 
PC 10mg/film 
Gelatin 20 
Glycerine 3 
Triethanolamine 0.3 
 
TABLE 2 : Physical characteristics of the prepared films 
Formulation 
Weight 
(mg±SD) 
Thickness 
(mm ± SD) 
Surface pH 
Drug content 
(mg) 
PC Gelatin film 28.47 ± 3.13 2.13 ± 0.012 5.8-6 9.6 ± 0.8 
 
*Results are presented as mean ± SD, n = 3. 
 
TABLE 3 : Mean Gingival index, Plaque Index and Sulcus Bleeding Index at baseline 
and 21 days  
Indices Baseline 21 days  p – value 
Gingival index 2.53 ± 0.67 1.43 ± 0.52 < 0.001* 
Plaque index 2.37 ± 0.62 1.39 ± 0.58 < 0.001* 
Sulcus Bleeding 
Index 
2.75 ± 0.28 1.75 ± 0.29 < 0.001* 
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TABLE 4 : Comparison of mean in PPD between Group I and Group II post-therapy. 
Probing 
pocket depth 
Group I 
Mean±SD 
Group II 
Mean±SD 
P 
Value 
Baseline 5.69 ± 0.00 5.74 ± 0.00 − 
21 days 2.92 ± 0.17 2.05 ± 0.62 < 0.001* 
 
 
TABLE 5 : Comparison of % of reduction in PPD between Group I and Group II 
post-therapy. 
PROBING POCKET 
DEPTH 
GROUP I GROUP II P VALUE 
 
% Reduction 
 
48.7% 
 
64.3% 
 
< 0.001* 
 
 
TABLE 6 : Comparison of mean in CAL between Group I and Group II post-therapy 
CLINICAL ATTACHMENT 
LEVEL 
Group I 
Mean±SD 
Group II 
Mean±SD 
P Value 
Baseline 3.69 ± 0.22 3.74 ± 0.38 − 
21 days 1.82 ± 0.48 0.82 ± 0.22 < 0.001* 
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TABLE 7 : Comparison of % of gain in CAL between Group I and Group II post-
therapy 
CLINICAL 
ATTACHMENT LEVEL 
GROUP I GROUP II P VALUE 
 
% GAIN 
 
51.5% 
 
79.1% 
 
< 0.001* 
 
 
TABLE 8 : Comparison of IL-1β levels between group I and group II at baseline and 
at 21 days post therapy 
IL-1β  GROUP I GROUP II P VALUE 
BASELINE 78.23 ± 0.36 79.36 ± 0.18 _ 
21 Days 59.53 ± 0.22 37.9 ± 0.83 < 0.05* 
 
 
TABLE 9 : Comparison of SOD levels between group I and group II at baseline and 
at 21 days post therapy 
SOD  GROUP I GROUP II P VALUE 
BASELINE 111.83 ± 0.97 124.56 ± 0.74 _ 
21 Days 189.73 ± 0.27 263.36 ± 0.23 < 0.05* 
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GRAPH 1 : UV-VIS spectra of Punicalagin 
 
 
GRAPH 2 : UV-VIS calibration curve of Punicalagin 
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GRAPH 3: Cumulative release profile of PC from Gelatin in buffer pH 6.6. 
Results represent mean ± SD, n = 3. 
 
 
GRAPH 4 : Mean Gingival Index, Plaque Index and Sulcus Bleeding Index at 
baseline and 21 days post-therapy.  
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GRAPH 5 : Probing Pocket Depth in both groups at baseline and 21 days post-
therapy 
 
GRAPH 6 : Clinical Attachment Level in both groups at baseline and 21 days post 
therapy 
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GRAPH 7 : Comparison of % of reduction in Probing Pocket Depth between Group I 
and Group II post-therapy   
 
GRAPH 8 : Comparison of % of gain in Clinical Attachment Level between Group I 
and Group II post-therapy 
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GRAPH 9 : IL-1β levels in both groups at baseline and 21 days post therapy 
 
GRAPH 10 : Superoxide Dismutase levels in both groups at baseline and 21 days post 
therapy 
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The ultimate goal of periodontal therapy is to reconstitute the tissues 
destroyed by periodontal disease. Scaling and Root Planing has been the ideal choice 
of procedure to treat periodontal disease but complete elimination of 
periodontopathogens and tissue destruction is impossible.[56] Local delivery of drugs 
along with Scaling and Root Planing offers greater advantage of high accessibility at 
the target site with limited side effects. Punicalagin is the major polyphenol isolated 
from pomegranate, shown to possess anti-inflammatory and anti-oxidant 
properties.[46] In the present study, punicalagin is used as a Local Drug Delivery, 
mode in the form of a gel along with Scaling and Root Planing for the treatment of 
Chronic Periodontitis patients. 
In this study, the mean plaque index score at baseline was found to be 2.37 ± 
0.62. After 21 days of treatment, the value was reduced to 1.39 ± 0.58. Statistically 
significant difference was found from baseline to 21 days post-treatment (p<0.001). 
This was in accordance with the study done by Bhadbhade et al[53] who showed 
significant reduction in plaque formation following mouth rinsing with Punica 
granatum mouthwash when compared to placebo. Punicalagin suppresses the ability 
of the microorganisms to adhere to the surface of the tooth and prevents the 
formation of plaque. Pomegranate also prevents the ability to adhere by interfering 
with substances such as extracellular polysaccharides that the bacteria use as a glue.  
In the present study, the mean gingival index score at baseline was 2.53 ± 
0.67 and reduced to 1.43 ± 0.52 after 21 days post-treatment. Sulcus Bleeding Index 
score at baseline was 2.75 ± 0.28 and was decreased to 1.75 ± 0.29 after 21 days 
post-therapy. There was a statistically significant reduction in both Sulcus Bleeding 
Index and gingival index after 21 days post-treatment (p<0.001). This was in 
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accordance with the study done by Sahgal et al[57] who reported that Punica 
granatum applied in a gel form was efficient in reducing the Gingival Index score 
because of its strong styptic action. The reduction in Sulcus Bleeding Index was in 
accordance with the study by Ahuja et al[58] where pomegranate mouthwash used 
two times daily for fifteen days resulted in more efficient decrease in bleeding on 
probing scores when compared to Chlorhexidine mouthwash. He also reported that 
Pomegranate was effective in reducing both gingival and bleeding on probing scores 
because of its strong styptic action.    
In the present study, group II showed more statistically significant reduction 
in Probing pocket depth and gain in Clinical Attachment level at 21 days post-
therapy when compared to group I. Group I showed Probing Pocket Depth of 5.69 ± 
0.00 at baseline which was reduced to 2.92 ± 0.17 at 21 days post-therapy. Group II 
showed Probing Pocket Depth of 5.74 ± 0.00 at baseline which was decreased to 
2.05 ± 0.62 at 21 days post-therapy. Clinical Attachment Loss for group I and group 
II at baseline were 3.69 ± 0.22 and 3.74 ± 0.38. Clinical Attachment Loss value was 
reduced to 1.82 ± 0.48 and 0.82 ± 0.22 at 21 days post-therapy respectively. Similar 
results were shown by Sastravaha et al[50] and reported that pomegranate extract 
provided significantly better results in decreasing the probing depth and attachment 
loss. Punicalagin has been shown to provide a synergistic action in collagen 
stabilization as they have the affinity for proteins and forming bonds with collagen 
fibers.  
In this study, IL-1β levels at baseline were 78.23 ± 0.36 and 79.36 ± 0.18 in 
group I and group II respectively. Levels were reduced to 59.53 ± 0.22 and 37.9 ± 
0.83 in group I and group II respectively at 21 days post treatment. There was 
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statistically significant decrease in the level of IL-1β after 21 days post-therapy in 
both the groups (p<0.001). When comparing between the groups, Group II showed 
more statistically significant (P<0.05) decrease in the level of IL-1β than group I at 
21 days post-therapy. Similar results were observed in a study done by Xu et al[59] 
who reported that punicalagin reduced the levels of secreted proinflammatory 
cytokines such as IL-1β, IL-6 and TNF-α. Pomegranate extract exhibited anti 
inflammatory activity through inhibition of NF-kB activity and prevention of ERK-1 
and ERK-2 activation. Pomegranate extract have been shown to inhibit the IL 1 beta 
induced destruction of proteoglycan, and also inhibits the expression of MMPs, 
Nitric Oxide and PGE2 production. Ahmed et al[60] also showed that Pomegranate 
extract exhibited anti-inflammatory property by inhibiting the IL-1β–induced 
expression of  MMP-1, -3, and -13 mRNA expression. Recently Xu et al[61] showed 
that Pomegranate extract produced potential anti-inflammatory effect through 
modulating the synthesis of several mediators and cytokines that are involved in the 
inflammatory process such as IL-1β and TNF-α 
In the present study, SuperOxide Dismutase levels at baseline were 111.83 ± 
0.97 and 124.56 ± 0.74 in group I and group II respectively. SuperOxide Dismutase 
Levels were increased to 189.73 ± 0.27 and 263.36 ± 0.23 in group I and group II 
respectively at 21 days post-therapy. When comparing between the groups, Group II 
showed more statistically significant (P<0.05) increase in the level of  SuperOxide 
Dismutase than Group I after 21 days post-therapy. This was supported by a study 
done by Gil et al[62] who showed that high antioxidant activity of Punica granatum 
was due to the presence of punicalagin isomers, ellagic acid derivatives and 
anthocyanins. Pomegranate extract inhibits lipopolysaccharide induced oxidative 
Discussion 
 
67 
 
stress by reducing Reactive Oxygen Species, Nitric Oxide generation and by 
increasing Superoxide Dismutase 1 mRNA expression.[46]  
 Based on the above results obtained in this study, there is an improvement in 
the clinical parameters with an increase in the anti-oxidant marker level and a 
decrease in inflammatory marker level when punicalagin gel was used along with 
Scaling and Root Planing in patients with Chronic Periodontitis. 
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The present study involved a comparative clinical and biochemical 
evaluation of punicalagin loaded gel along with Scaling and Root Planing (SRP) and 
SRP alone in patients with Chronic Periodontitis.  
Within the framework of this study, the following conclusions have been 
elucidated, 
1. The adjunctive use of Punicalagin in addition to Scaling and Root 
Planing(SRP) resulted in better treatment response when compared to 
SRP alone. 
2. Probing Pocket Depth reduction and gain in attachment level were 
significant in both the groups when compared to baseline. When 
compared between the groups, Group II showed more Probing Pocket 
Depth reduction and Clinical Attachment Level gain at 21 days post 
treatment with a statistically significant p value of < 0.001. 
3. A decrease in IL-1β levels and an increase in SOD levels were also seen 
in both the groups with significant difference at 21 days when compared 
to baseline. When compared between the groups, Group II showed more 
statistically significant decrease in IL-1β levels and increase in 
Superoxide Dismutase levels than Group I.     
The results showed that punicalagin has the potential to serve as a 
therapeutic agent to treat chronic periodontitis patients. Compared to Scaling and 
Root Planing alone, adjunctive use of punicalagin showed greater probing Pocket 
Depth reduction, Clinical Attachment Level gain and favourable changes in 
inflammatory and anti-oxidant markers. 
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 However, limitations of this study includes a small sample size and a short 
term follow up. In order to evaluate long term benefit of punicalagin as a therapeutic 
agent, a long term study with a larger sample size is required. 
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